Jazz Raising Hematology/Oncology Reach Further With ImmunoGen Deal
Ireland-based Jazz Pharma is extending its shift away from specialty pharma with an option-based deal with ImmunoGen involving three antibody-drug conjugate programs.
You may also be interested in...
This year's ASH meeting reflected a peak of development success, with many new approvals and many more in the pipeline.
Public Company Financings: Rhythm and OptiNose are the 30th and 31st initial public offerings of 2017. Also, reverse mergers add two more newly public firms, Valeant raises $1bn to pay down more debt, and PhaseRx and Trevena cut jobs.
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.